Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma / ESMO
esmo - Findings from the ZSAB-neoGOLP study
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch #clinicaltrials
Monday, March 16, 2026, 3:21 am / permalink 20797 / 3 stories in 15 hrs
NRG-LU005 Trial: Atezolizumab Plus Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer / OncoDaily
oncodaily - A major international clinical trial, NRG-LU005, has provided important new insight into how immunotherapy should be used in limited-stage small cell lung cancer (SCLC). While immune checkpoint inhibitors have significantly […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch
Monday, March 16, 2026, 12:23 am / permalink 20789 / 4 stories in 18 hrs
FDA Drug Approval Marks a First for a Disease — But It’s Not Autism / MedCity
Frank Vinluan / medcitynews - Leucovorin is now approved for cerebral folate deficiency months after FDA Commissioner Marty Makary claimed the decades-old generic drug had promise for treating autism. The FDA’s review was based on published literature and real-world evidence.The post …
#healthcare #pharmaceuticals #publichealth #governmentpolicy #drugdevelopment #fda #autism
Sunday, March 15, 2026, 12:22 pm / permalink 20779 / 4 stories in 30 hrs
A new triple negative breast cancer target: Why HORMAD1 could guide treatment choices / Medical Express
medicalxpress - A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature Communications. Scientists from the Breast Cancer Now Toby Robins Re…
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch
Saturday, March 14, 2026, 11:21 pm / permalink 20776 / 4 stories in 43 hrs
Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision / MedCity
Frank Vinluan / medcitynews - GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concer…
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #healthcarefinance
Saturday, March 14, 2026, 8:21 pm / permalink 20771 / 2 stories in 46 hrs
Roche’s big hope breast cancer drug fails in crucial first-line trial / Endpoints
Elizabeth Cairns / endpoints - Roche’s breast cancer pill, which the company recently said had the potential to become its biggest-ever selling drug, has failed in what is arguably its most important Phase 3 trial. The persevERA ...
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch
Saturday, March 14, 2026, 7:21 pm / permalink 20770 / 5 stories in 47 hrs
‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up / MedCity
Marissa Plescia / medcitynews - Novo Nordisk dropped its lawsuit against Hims & Hers and launched a new collaboration. The deal is advantageous for both companies, experts say.The post ‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up appeared first on MedCity News.
#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #digitalhealth #healthcarefinance #supplychain
Saturday, March 14, 2026, 2:22 pm / permalink 20763 / 3 stories in 2 days
Antonio Calles: RECITE Trial Findings on Romiplostim for Chemotherapy-Induced Thrombocytopenia / OncoDaily
oncodaily - Antonio Calles, Medical Oncologist at Hospital General Universitario Gregorio Marañón and faculty member of the Lung and Other Thoracic Tumours faculty group of the ESMO, shared a post by NEJM, […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch
Saturday, March 14, 2026, 12:23 pm / permalink 20760 / 2 stories in 2 days
Ipsen pulls cancer drug Tazverik from market over safety risks / Endpoints
Nicole DeFeudis / endpoints - Ipsen is pulling its cancer drug Tazverik from the market after an independent data monitoring committee found safety concerns in a confirmatory trial. The committee reported cases of secondary cancers that begin in blood-forming tissue ...
#healthcare #pharmaceuticals #biotech #drugdevelopment #fda #productrecall #oncology #cancerresearch
Saturday, March 14, 2026, 12:23 am / permalink 20738 / 3 stories in 2 days
Eliquis may be safer than Xarelto for patients with deep blood clots: Study / Beckers
Ella Jeffries / beckershospitalreview - Patients taking blood thinner Eliquis had a lower risk of clinically relevant bleeding than those taking Xarelto, a recent study found. Researchers enrolled 2,760 patients with venous thrombosis — blood clots in the veins of the legs or lungs — and random…
#healthcare #pharmaceuticals #publichealth #drugdevelopment
Saturday, March 14, 2026, 12:23 am / permalink 20737 / 2 stories in 2 days
Flu vaccines didn't work that well in the US, officials find / Medical Express
medicalxpress - As the U.S. flu season winds down, health officials say the flu vaccine didn't work very well, with one of its worst effectiveness rates in more than a decade.
#healthcare #pharmaceuticals #publichealth #drugdevelopment #cdc #vaccinesafety #infectiousdisease
Saturday, March 14, 2026, 12:23 am / permalink 20736 / 3 stories in 2 days
FDA Transparency Push Expands to Monitoring Safety of Vaccines and Other Regulated Products / MedCity
Frank Vinluan / medcitynews - The FDA said consolidating safety reporting into a single platform, the Adverse Event Monitoring System (AEMS), will increase transparency and reduce costs. But like the legacy systems it replaces, AEMS reports are unverified so causation and frequency of…
#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #fda #vaccinesafety #digitalhealth #animalhealth
Thursday, March 12, 2026, 5:23 pm / permalink 20659 / 6 stories in 4 days
Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors / Science Translational Medecine
Torahito A. Gao, Ryan M. Shih, Justin D. Clubb, Shao-Hsi Hung, Tanya Singh, Laura B. James-Allan, Ga / science - Science Translational Medicine, Volume 18, Issue 839, March 2026.
#pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch
Monday, March 9, 2026, 4:22 am / permalink 20364 / 18 stories in 7 days
White House autism briefing linked to swift shifts in prescribing patterns / Medical Express
medicalxpress - A White House briefing in September 2025 that raised concerns about acetaminophen use during pregnancy and promoted the drug leucovorin as a potential autism treatment was followed by sharp changes in how doctors prescribed those medications nationwide, a…
#healthcare #pharmaceuticals #publichealth #governmentpolicy #infanthealth #hospitaloperations
Monday, March 9, 2026, 12:22 am / permalink 20354 / 4 stories in 7 days
Eli Lilly's new program aims to boost employer coverage of GLP-1s / Endpoints
Shelby Livingston / endpoints - With insurance coverage of weight loss medications stalled, Eli Lilly has developed a program to give employers another way to pay for their workers' GLP-1 treatments. The pharma giant on Thursday announced the launch of ...
#obesity #healthcare #pharmaceuticals #drugpricing #elililly #weightloss #healthcarefinance
Saturday, March 7, 2026, 10:21 pm / permalink 20341 / 33 stories in 8 days
ASCO GU 2026 Highlights: Belzutifan + Lenvatinib and Pembrolizumab in RCC – IUCS / OncoDaily
oncodaily - International Urology Cancer Summit shared a post on LinkedIn: “IUCS Journal Club – Highlights from ASCO GU 2026: Targeting HIF-2α in RCC. This Journal Club session reviews the data from […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology
Saturday, March 7, 2026, 9:22 am / permalink 20321 / 6 stories in 9 days
New FDA bonus pilot to address 'workforce challenges' / Endpoints
Max Bayer / endpoints - A new bonus pilot program meant to reward fast-working FDA reviewers will be funded in part by money from industry user fees, the first details on how Commissioner Marty Makary plans to finance the incentive ...
#healthcare #pharmaceuticals #governmentpolicy #biotech #drugdevelopment #fda #healthcarefinance
Saturday, March 7, 2026, 12:23 am / permalink 20312 / 2 stories in 9 days
FDA lifts hold on Intellia trial / Beckers
Ella Jeffries / beckershospitalreview - The FDA has lifted a clinical hold on Intellia Therapeutics’ phase 3 Magnitude trial of nexiguran ziclumeran, or nex-z. The trial was paused Oct. 29 after a patient developed grade 4 liver transaminase elevations and elevated bilirubin following a Sept. 3…
#healthcare #pharmaceuticals #biotech #drugdevelopment #fda
Saturday, March 7, 2026, 12:23 am / permalink 20309 / 4 stories in 9 days
Optum Rx, Caremark making ‘significant progress’ in settlement talks with FTC / Healthcare Dive
Rebecca Pifer Parduhn / healthcaredive - It’s looking increasingly likely that the UnitedHealth and CVS drug middlemen will also make peace with federal regulators, after Cigna agreed to a sweeping settlement in the insulin lawsuit last month.
#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy #healthcarefinance
Saturday, March 7, 2026, 12:23 am / permalink 20308 / 3 stories in 9 days
Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology / MedCity
Frank Vinluan / medcitynews - Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If Moderna’s full financial payout to the companies is reache…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #healthcarefinance #infectiousdisease
Saturday, March 7, 2026, 12:22 am / permalink 20307 / 3 stories in 9 days